Download Library

 
 
 
Download Library
Document Type
Jefferies London Healthcare Conference, London, UK - November 2016
PDF
1.8 MB
Capital Markets Day Presentation - November 2016
PDF
9.0 MB
Frontline Ofatumumab in Combination with Hyper-CVAD for Patients with CD-20 Positive ALL: Interim Result of a Phase II Trial - ASH abstract - November 2016 (Sasaki)
URL
N/A
DRd Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) - ASH abstract - November 2016 (Chiu)
URL
N/A
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH abstract - November 2016 (Caillon)
URL
N/A
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH abstract - November 2016 (Adams)
URL
N/A
Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed CLL in the United States - ASH abstract - November 2016 (Tremblay)
URL
N/A
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH abstract - November 2016 (Usmani)
URL
N/A
Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH abstract - November 2016 (Moreau)
URL
N/A
Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
URL
N/A
Daratumumab in combination with Dexamethasone in Resistant or Refractory MM - ASH abstract - November 2016 (Boyle)
URL
N/A
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH abstract - November 2016 (Xu)
URL
N/A
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH abstract - November 2016 (Rigalou)
URL
N/A
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH abstract - November 2016 (Hájek)
URL
N/A
DVd Versus Vd Alone for Relapsed or Refractory MM Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor - ASH abstract - November 2016 (Chanan-Khan)
URL
N/A
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau)
URL
N/A
Clinical Efficacy of Daratumumab, Pomalidomide & Dexamethasone in Relapsed, Refractory Myeloma: Utility of Retreatment with Daratumumab Among Refractory Patients - ASH abstract - November 2016 (Nooka)
URL
N/A
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH abstract - November 2016 (Usmani)
URL
N/A
Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH abstract - November 2016 (Mateos)
URL
N/A
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH abstract - November 2016 (Kumar)
URL
N/A
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
URL
N/A
Q3 2016 Results Presentation
PDF
249.6 KB
Interim Report for the Nine Months Ended September 30, 2016
pdf
715.6 KB
Q3 2016 Results Podcast
MP3
23.5 MB
Bank of America Merrill Lynch Global Healthcare Conference, London, UK - September 2016
PDF
988.3 KB

Page: First Previous
1
2
3
4
5
6
7
8
...
18
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Årsregnskab 2001
PDF
429.6 KB
Kvartalsrapport - 3. kvartal 2000
PDF
59.2 KB
Årsregnskab 2000
PDF
592.8 KB
Page: First Previous
1
2
3
4